The size of the Asia Pacific Aptamers Market has been forecasted at USD 33.42 million in 2020 and will reach USD 92.18 million by the end of 2025, scoring a CAGR of 22.5% between 2020 to 2025.
Aptamers are oligonucleotides that bind to a target protein, lipid, or nucleic acid molecules with high specificity. Aptamers can be chosen from a pool of random-sequence oligonucleotides to bind a wide range of biomedically relevant proteins with specificities and affinities that are as good as antibodies. Aptamers are multipurpose and cost-effective which offer alternative solutions to the antibodies. Aptamers exhibit important advantages relative to protein therapeutics in terms of synthetic accessibility, size, and modification by medicinal chemistry.
The Major factors driving the growth of the Asia - Pacific market are an advancement in technology, Growing R&D investments in pharmaceutical and biotechnology industries, low cost, and high efficacy of aptamers in binding. Ethical issues for the aptamers that are obtained from animals, Stringent regulations in the use of aptamers may hinder the growth of the market.
This research report segmented and sub-segmented the Asia Pacific Aptamers Market into the following categories:
By Type:
By Application:
By End User:
By Country:
Some of the Prominent companies dominating the Asia Pacific Aptamers market are AM Biotechnologies, Aptagen, Aptamer Sciences Inc., Aptamer Solutions Ltd., Aptus Biotech S.L., Base Pair Biotechnologies Inc., NeoVentures Biotechnology Inc., SomaLogic Inc, TriLink BioTechnologies Inc., and Vivonics, Inc.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Type
5.1.1 Peptide Aptamers
5.1.2 Nucleic Acid Aptamers
5.1.2.1 DNA-Based Aptamers
5.1.2.2 RNA-Based Aptamers
5.1.2.3 XNA-Based Aptamers
5.2 By Application
5.2.1 Therapeutics Development
5.2.2 Diagnostics
5.2.3 Research and Developments
5.3 By End Users
5.3.1 Pharmaceutical Companies
5.3.2 Bio-Pharmaceutical Companies
5.3.3 Academic and Research Centers
6. Geographical Analysis
6.1 Introduction
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 AM Biotechnologies
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Aptagen
8.3 Aptamer Sciences Inc.
8.4 Aptamer Solutions Ltd
8.5 Aptus Biotech S.L.
8.6 Base Pair Biotechnologies Inc
8.7 NeoVentures Biotechnology Inc.
8.8 SomaLogic Inc
8.9 TriLink BioTechnologies Inc
8.10 Vivonics, Inc
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Feb 2020